BS_4A45GGSW
pilocytic astrocytoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- pilocytic astrocytoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- pilocytic astrocytoma
- overall_survival_months
- 47.56898817345598
- age_years
- 13.025
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.551
- PROTEIN_SECRETION+0.550
- TGF_BETA_SIGNALING+0.465
- HYPOXIA+0.404
- ADIPOGENESIS+0.378
- IL6_JAK_STAT3_SIGNALING+0.362
- P53_PATHWAY+0.346
- GLYCOLYSIS+0.336
- ANDROGEN_RESPONSE+0.326
- COMPLEMENT+0.321
Top 10 suppressed
- E2F_TARGETS-0.435
- G2M_CHECKPOINT-0.355
- MYC_TARGETS_V2-0.250
- PANCREAS_BETA_CELLS-0.226
- KRAS_SIGNALING_DN-0.186
- MYC_TARGETS_V1-0.183
- SPERMATOGENESIS-0.173
- DNA_REPAIR-0.023
- WNT_BETA_CATENIN_SIGNALING-0.017
- MITOTIC_SPINDLE+0.004
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_42Y3YANN | pilocytic astrocytoma | — | 0.928 |
| 2 | BS_BKQZ550R | pilocytic astrocytoma | — | 0.926 |
| 3 | BS_Q79NP5YY | pilocytic astrocytoma | — | 0.923 |
| 4 | BS_FJWZ3M7V | low-grade glioma | — | 0.903 |
| 5 | BS_SDZY6RZ3 | pilocytic astrocytoma | — | 0.902 |
| 6 | BS_N1E0H8YQ | low-grade glioma | — | 0.896 |
| 7 | BS_T0RKFEKR | pilocytic astrocytoma | — | 0.892 |
| 8 | BS_T4JFN54G | low-grade glioma | — | 0.892 |
| 9 | BS_49852ZBH | pilocytic astrocytoma | — | 0.885 |
| 10 | BS_2YCJV2VV | low-grade glioma | — | 0.884 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.551 | Remibrutinib | — uncovered |
| PROTEIN_SECRETION | 0.550 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.465 | Inavolisib | — uncovered |
| HYPOXIA | 0.404 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.378 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.362 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.346 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.336 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.326 | Inavolisib | — uncovered |
| COMPLEMENT | 0.321 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.317 | Inavolisib | — uncovered |
| COAGULATION | 0.315 | Binimetinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.315 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.315 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.308 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.307 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.307 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.296 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.284 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.284 | Idelalisib | — uncovered |